Diagnosis and therapy of ulcerative colitis: Cancer prevention;Diagnostik und theraoie der colitis ulcerosa: Karzinomprophylaxe

Zeitschrift fur Gastroenterologie

Volumn 42, Issue 9, 2004, Pages 1014-1017

  Schmiegel, W ^a   Pox, C ^a   Kroesen, A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

SALICYLIC ACID; URSODEOXYCHOLIC ACID; ACETYLSALICYLIC ACID; CHOLAGOGUE; FOLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT;

CANCER PREVENTION; CANCER RISK; CARCINOGENICITY; COLON ADENOMA; COLORECTAL CARCINOMA; CONFERENCE PAPER; HUMAN; INTESTINE BIOPSY; PROCTOCOLECTOMY; ULCERATIVE COLITIS; ADENOMA; ADULT; ARTICLE; BIOPSY; CASE CONTROL STUDY; CHILD; COLON; COLON POLYPOSIS; COLON RESECTION; COLORECTAL TUMOR; CROSS-SECTIONAL STUDY; FEMALE; FOLLOW UP; MALE; META ANALYSIS; PATHOLOGY; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SCLEROSING CHOLANGITIS; TIME;

ADENOMA; ADENOMATOUS POLYPOSIS COLI; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; BIOPSY; CASE-CONTROL STUDIES; CHILD; CHOLAGOGUES AND CHOLERETICS; CHOLANGITIS, SCLEROSING; COLECTOMY; COLITIS, ULCERATIVE; COLON; COLORECTAL NEOPLASMS; CROSS-SECTIONAL STUDIES; FEMALE; FOLIC ACID; FOLLOW-UP STUDIES; HUMANS; MALE; META-ANALYSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; URSODEOXYCHOLIC ACID;

EID: 10344240972     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-813513     Document Type: Conference Paper

References (53)

1. Gilat T, Fireman Z, Grossman A et al. Colorectal cancer in patients with ulcerative colitis. A population study in central Israel. Gastroenterology 1998; 94: 870-877 (IIa)
2. Gyde SN, Prior P, Allan RN et al. Colorectal cancer in ulcerative colitis: a cohort study of primary referrals from three centres. Gut 1988; 29: 206-217 (IIa)
3. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001; 48: 526-535 (IIa)
4. Soetikno RM, Lin OS, Heidenreich PA et al. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc 2002; 56: 48-54 (IIa)
5. Ekbom A, Helmick C, Zack M et al. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 1990; 323: 1228-1233 (IIb)
6. D'Haens GR, Lashner BA, Hanauer SB. Pericholangitis and sclerosing cholangitis are risk factors for dysplasia and cancer in ulcerative colitis. Am J Gastroenterol 1993; 88: 1174-1178 (III)
7. Broome U, Lofberg R, Veress B et al. Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology 1995; 22: 1404-1408 (IIa)
8. Porschen R, Holzmann K, Klump B et al. The role of flow cytometry in surveillance strategies in patients with ulcerative colitis. In: Emmrich J, Liebe S, Stange EF (Hrsg). Innovative concepts in inflammatory bowel diseases. Boston, London: Kluwer Academic Publishers, 1999; 243-253 (IIa)
9. Holzmann K, Klump B, Borchard F et al. Flow cytometric and histologic evaluation in a large cohort of patients with ulcerative colitis: correlation with clinical characteristics and impact on surveillance. Dis Colon Rectum 2001; 44: 1446-1455 (IIb)
10. Heuschen UA, Heuschen G, Stern J. Backwash ileitis in ulcerative colitis - new aspects in the assessment of the disease 1997, 245-249. In: Andus T, Goebell H, Layer P, Schölmerich J (Hrsg). Inflammatory bowel diseases - from bench to bedside. Dordrecht, Boston, London: Kluwer Academic Publishers, 1997; 245-249 (III)
11. Bansal P, Sonnenberg A. Risk factors of colorectal cancer in inflammatory bowel disease. Am J Gastroenterol 1996; 91: 44-48 (III)
12. Rutter M, Saunders B, Wilkinson K et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004; 126: 451-459 (IIb)
13. Sugita A, Sachar DB, Bodian C et al. Colorectal cancer in ulcerative colitis. Influence of anatomical extent and age at onset on colitis-cancer interval. Gut 1991; 32: 167-169 (III)
14. Mellemkjaer L, Olsen JH, Frisch M et al. Cancer in patients with ulcerative colitis. Int J Cancer 1995; 60: 330-333 (IIa)
15. Mir-Madjlessi SH, Farmer RG, Easley KA et al. Colorectal and extra-colonic malignancy in ulcerative colitis. Cancer 1986; 58: 1569-1574 (IIb)
16. Prior P, Gyde SN, Macartney JC et al. Cancer morbidity in ulcerative colitis. Gut 1982; 23: 490-497 (III)
17. Wee A, Ludwig J, Coffey RJ Jr et al. Hepatobiliary carcinoma associated with primary sclerosing cholangitis and chronic ulcerative colitis. Hum Pathol 1985; 16: 719-726 (IV)
18. Ahrendt SA, Pitt HA, Nakeeb A et al. Diagnosis and management of cholangiocarcinoma in primary sclerosing cholangitis. J Gastrointest Surg 1999; 3: 357-367; discussion 367-368 (III)
19. Pinczowski D, Ekbom A, Baron J et al. Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study. Gastroenterology 1994; 107: 117-120 (III)
20. Moody GA, Jayanthi V, Probert CS et al. Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur J Gastroenterol Hepatol 1996; 8: 1179-1183 (IIb)
21. Eaden J, Abrams K, Ekbom A et al. Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther 2000; 14: 145-153 (IIa)
22. Tung BY, Emond MJ, Haggitt RC et al. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med 2001; 134: 89-95 (IIb)
23. Pardi DS, Loftus EV Jr, Kremers WK et al. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003; 124: 889-893 (IIb)
24. Biasco G, Zannoni U, Paganelli GM et al. Folic acid supplementation and cell kinetics of rectal mucosa in patients with ulcerative colitis. Cancer Epidemiol Biomarkers Prev 1997; 6: 469-471 (Ib)
25. Lashner BA, Heidenreich PA, Su GL et al. Effect of folate supplementation on the incidence of dysplasia and cancer in chronic ulcerative colitis. A case-control study. Gastroenterology 1989; 97: 255-259 (III)
26. Lashner BA, Provencher KS, Seidner DL et al. The effect of folic acid supplementation on the risk for cancer or dysplasia in ulcerative colitis. Gastroenterology 1997; 112: 29-32 (III)
27. Fiedler L, Rubin P, Korelitz B. Does folate supplementation really protect from dysplasia and cancer in ulcerative colitis? a case control study. Gastroenterology 1993; 104: A546 (III)
28. Choi PM, Nugent FW, Schoetz DJ Jr et al. Colonoscopic surveillance reduces mortality from colorectal cancer in ulcerative colitis. Gastroenterology 1993; 105: 418-424 (III)
29. Connell WR, Talbot IC, Harpaz N et al. Clinicopathological characteristics of colorectal carcinoma complicating ulcerative colitis. Gut 1994; 35: 1419-1423 (IIb)
30. Giardiello FM, Gurbuz AK, Bayless TM. Colorectal cancer in ulcerative colitis: effect of a cancer prevention strategy on survival. Gastroenterology 1993; 104: A502 (III)
31. Jablonska M. Management of cancer surveillance in ulcerative colitis. Gut 1995; 37 (Suppl. 2): A90 (III)
32. Karlen P, Kornfeld D, Brostrom O et al. Is colonoscopic surveillance reducing colorectal cancer mortality in ulcerative colitis? A population based case control study. Gut 1998; 42: 711-714 (III)
33. Melville DM, Jass JR, Shepherd NA et al. Dysplasia and deoxyribonucleic acid aneuploidy in the assessment of precancerous changes in chronic ulcerative colitis. Observer variation and correlations. Gastroenterology 1988; 95: 668-675 (IIa)
34. Lim CH, Dixon MF, Vail A et al. Ten year follow up of ulcerative colitis patients with and without low grade dysplasia. Gut 2003; 52: 1127-1132 (IIb)
35. Dixon MF, Brown LJ, Gilmour HM et al. Observer variation in the assessment of dysplasia in ulcerative colitis. Histopathology 1988; 13: 385-397 (Ib)
36. Eaden J, Abrams K, McKay H et al. Inter-observer variation between general and specialist gastrointestinal pathologists when grading dysplasia in ulcerative colitis. J Pathol 2001; 194: 152-157 (IIb)
37. Greenstein AJ, Sachar DB, Smith H et al. Cancer in universal and left-sided ulcerative colitis: factors determining risk. Gastroenterology 1979; 77: 290-294 (IIb)
38. Connell WR, Lennard-Jones JE, Williams CB et al. Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis. Gastroenterology 1994; 107: 934-944 (IIa)
39. Grundfest SF, Fazio V, Weiss RA et al. The risk of cancer following colectomy and ileorectal anastomosis for extensive mucosal ulcerative colitis. Ann Surg 1981; 193: 9-14 (III)
40. Kurtz LM, Flint GW, Platt N et al. Carcinoma in the retained rectum after colectomy for ulcerative colitis. Dis Colon Rectum 1980; 23: 346-350 (IV)
41. Kiesslich R, Fritsch J, Holtmann M et al. Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology 2003; 124: 880-888 (Ib)
42. Fleischer DE. Chromoendoscopy and magnification endoscopy in the colon. Gastrointest Endosc 1999; 49: S45-S49 (III)
43. Heinzlmann M, Lang SM, Neynaber S et al. Screening for p53 and K-ras mutations in whole-gut lavage in chronic inflammatory bowel disease. Eur J Gastroenterol Hepatol 2002; 14: 1061-1066 (IIb)
44. Markowitz J, McKinley M, Kahn E et al. Endoscopic screening for dysplasia and mucosal aneuploidy in adolescents and young adults with childhood onset colitis. Am J Gastroenterol 1997; 92: 2001-2006 (III)
45. Rubin CE, Haggitt RC, Burmer GC et al. DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis. Gastroenterology 1992; 103: 1611-1620 (Ib)
46. Taylor BA, Pemberton JH, Carpenter HA et al. Dysplasia in chronic ulcerative colitis: implications for colonoscopic surveillance. Dis Colon Rectum 1992; 35: 950-956 (III)
47. Bernstein CN, Shanahan F, Weinstein WM. Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis? Lancet 1994; 343: 71-74 (III)
48. Ullman T, Croog V, Harpaz N et al. Progression of flat low-grade dysplasia to advanced neoplasia in patients with ulcerative colitis. Gastroenterology 2003; 125: 1311-1319 (III)
49. Befrits R, Ljung T, Jaramillo E et al. Low-grade dysplasia in extensive, long-standing inflammatory bowel disease: a follow-up study. Dis Colon Rectum 2002; 45: 615-620 (III)
50. Provenzale D, Kowdley KV, Arora S et al. Prophylactic colectomy or surveillance for chronic ulcerative colitis? A decision analysis. Gastroenterology 1995; 109: 1188-1196 (III)
51. Engelsgjerd M, Farraye FA, Odze RD. Polypectomy may be adequate treatment for adenoma-like dysplastic lesions in chronic ulcerative colitis. Gastroenterology 1999; 117: 1288-1294; discussion 1488-1491 (III)
52. Rubin PH, Friedman S, Harpaz N et al. Colonoscopic polypectomy in chronic colitis: conservative management after endoscopic resection of dysplastic polyps. Gastroenterology 1999; 117: 1295-1300 (III)
53. Rozen P, Baratz M, Fefer F et al. Low incidence of significant dysplasia in a successful endoscopic surveillance program of patients with ulcerative colitis. Gastroenterology 1995; 108: 1361-1370 (III)